Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

NSE/GLENMARK stock hub

NSE/GLENMARK has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

NSE/GLENMARKis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

667.8B

National Stock Exchange of India

Market data

Live price

Current market quote for this ticker.

Current price

NSE/GLENMARK

In the news

Latest news · NSE/GLENMARK

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E29.8

P25 24.9P50 32.4P75 45.7

Trailing P/E62.7

P25 24.8P50 35.9P75 56.9

ROEn/a

P25 6.3P50 13.6P75 18.1

ROIC31.6

P25 4.1P50 10.3P75 17.9

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All NSE/GLENMARK market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

200

Groups with data

Currency

INR

Showing 200 of 200 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	India
Country code	IN
Employees	15,800
Employees Change	811%
Employees Change Percent	5.41
Enterprise value	INR 653.1B
Exchange	National Stock Exchange of India
Financial currency	INR
First seen	2026-05-10
Industry	Drug Manufacturers - Specialty & Generic
Isin	INE935A01035
Last refreshed	2026-05-10
Market cap	INR 667.8B
Price	INR 2,368
Price currency	INR
Rev Per Employee	10,449,168.35x
Sector	Healthcare
Sic	2834
Symbol	nse/GLENMARK
Website	https://glenmarkpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	1.59%
EV Earnings	61.32x
EV/EBIT	16.91x
EV/EBITDA	15.82x
EV/Sales	3.96x
Forward P/E	29.85x
P/B ratio	6.97x
P/E ratio	62.7x
P/S ratio	4.04x
PE Ratio10 Y	25.19x
PE Ratio5 Y	31.99x
PEG ratio	1.35x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	23.39%
EBITDA Margin	24.41%
Gross margin	70.71%
Gross Profit	INR 116.7B
Gross Profit Growth	22.43%
Gross Profit Growth Q	13.12%
Gross Profit Growth3 Y	12.97%
Gross Profit Growth5 Y	11.12%
Net Income	INR 10.7B
Net Income Growth Q	15.88%
Net Income Growth Quarters	2%
Net Income Growth Years	1%
Net Income Growth3 Y	6.52%
Net Income Growth5 Y	2.17%
Pretax Margin	9.72%
Profit Margin	6.45%
Profit Per Employee	INR 674,106
Profitable Years	1
Roa5y	6.24
Roe5y	3.55
ROIC	31.58
Roic5y	-133

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	11.6%
Cagr15y	15.54%
Cagr1y	65.47%
Cagr20y	14.43%
Cagr3y	62.94%
Cagr5y	32.45%
Div CAGR10	9.6%
Div CAGR3	25.99%
Div CAGR5	14.87%
EPS Growth Q	15.82
EPS Growth Quarters	2
EPS Growth Years	1
EPS Growth3 Y	6.53
EPS Growth5 Y	2.17
Revenue Growth	18.26x
Revenue Growth Q	15.15x
Revenue Growth Quarters	3x
Revenue Growth Years	2x
Revenue Growth3 Y	9.32x
Revenue Growth5 Y	8.9x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Cash	INR 26.9B
Debt	INR 12.2B
Debt EBITDA	INR 0.3
Debt Equity	INR 0.13
Equity	INR 95.8B
Interest Coverage	16.59
Net Cash	INR 14.7B
Net Cash By Market Cap	INR 2.2
Net Cash Growth	3,621.45%
Net Debt EBITDA	INR -0.36
Net Debt Equity	INR -0.15
Tangible Book Value	INR 77.7B
Tangible Book Value Per Share	INR 275
WACC	6.09

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-0.04%
Dividend Growth	100%
Dividend Growth Years	1%
Dividend per share	INR 5
Dividend Years	17
Dividend Yield	0.21%
Last Dividend	INR 2.5
Payout Frequency	Semi-Annual

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	199.49%
1Y total return	65.41%
200-day SMA	2,038.5
3Y total return	332.7%
50-day SMA	2,201
50-day SMA vs 200-day SMA	50over200
5Y total return	307.6%
All Time High	2,474
All Time High Change	-4.28%
All Time High Date	2026-04-29
All Time Low	4.62
All Time Low Change	51,188.72%
All Time Low Date	2001-08-13
ATR	69.72
Beta	0.31
Beta1y	0.6
Beta2y	0.49
Ch YTD	16.35
High	2,384.9
High52	2,474
High52 Date	2026-04-29
High52ch	-4.28%
Low	2,315.8
Low52	1,355.4
Low52 Date	2025-05-12
Low52ch	74.71%
Ma50ch	7.59%
Price vs 200-day SMA	16.17%
RSI	61.64
RSI Monthly	71.84
RSI Weekly	72.84
Sharpe ratio	1.86x
Sortino ratio	3.65
Total Return	0.17%
Tr YTD	16.35
Tr15y	773%
Tr1m	12.01%
Tr1w	-1.07%
Tr3m	22.39%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	INR 38.6B
Operating Income Growth	47.68
Operating Income Growth Q	49.8
Operating Income Growth3 Y	35.65
Operating Income Growth5 Y	20.89
Operating margin	23.39

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	141,594,752%
Shares Insiders	3.12%
Shares Institutions	37.75%
Shares Out	282,200,809
Shares Qo Q	0.02%
Shares Yo Y	0.04%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	698,396.75x
Bv Per Share	339.6
Ch10y	188.6
Ch15y	728.4
Ch1m	12.01
Ch1w	-1.07
Ch1y	65.01
Ch20y	1,298.7
Ch3m	22.39
Ch3y	329.8
Ch5y	300.3
Ch6m	30.72
Change	-0.15%
Change From Open	0.77
Close	2,371.6
Days Gap	-0.91
Depreciation Amortization	1,681,652,500
Dollar Volume	1,663,394,496
Earnings Date	2026-05-22
EBIT	INR 38.6B
EBITDA	INR 40.3B
EPS	INR 37.74
F Score	2
Fiscal Year End	March
Founded	1,977
Graham Number	536.98848
Graham Upside	-77.32
Income Tax	INR 5.4B
Is Primary Listing	1
Last Earnings Date	2026-01-30
Last Report Date	2025-12-31
Last Split Date	2007-09-10
Last Split Type	Forward
Lynch Fair Value	INR 189
Lynch Upside	-92.03
Ma150	2,031.7
Ma150ch	16.55%
Ma20	2,304.9
Ma20ch	2.74%
Next Earnings Date	2026-05-22
Open	2,350
Payment Date	2025-10-26
Position In Range	75.54
Price Date	2026-05-08
Price EBITDA	INR 16.57
Ptbv Ratio	8.59
Relative Volume	1.02x
Revenue	165,096,860,000x
Tax By Revenue	3.27x
Tax Rate	33.64%
Tr20y	1,382.76%
Tr6m	30.72%
Volume	702,447

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

NSE/GLENMARK dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+0.2%

$5.00 annual per share

Payout ratio

n/a

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

+14.9%

1 consecutive years of growth

Total shareholder yield

+0.2%

Dividend yield + buyback yield combined

Performance

NSE/GLENMARK stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns NSE/GLENMARK?

Insider, institutional, and short-interest positioning.

Institutional ownership

+37.8%

Share of float held by funds and institutions

Insider ownership

+3.1%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+0.0%

Negative means the company is buying back shares.

Technical

NSE/GLENMARK momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

61.6

Neutral momentum band

Price vs 200-day MA

+16.2%

50/200-day relationship not available

Beta (5Y)

0.31

Less volatile than the market

Sharpe ratio

1.86

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About NSE/GLENMARK

Hub-level FAQ points readers to the deeper analysis pages.

What is the current nse/GLENMARK stock rating?

nse/GLENMARK is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full nse/GLENMARK analysis?

The full report lives at /stocks/nse/GLENMARK/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for nse/GLENMARK?

The latest report frames nse/GLENMARK around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the nse/GLENMARK page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.